2024-05-10 11:08Financial Performance - The company's revenue for Q1 2024 reached CNY 5,359,338,000, representing a 74.8% increase compared to the same period last year[4] - The net profit attributable to shareholders was CNY -1,908,056,000, with a basic and diluted earnings per share of CNY -1.41[4] - The adjusted operating loss for the reporting period was CNY 937,000,000, an improvement from the adjusted operating loss of CNY 1,640,000,000 in the same period last year[9] - Total revenue for Q1 2024 reached RMB 5,359,338 thousand, a significant increase of 75% compared to RMB 3,066,389 thousand in Q1 2023[17] - Net loss for Q1 2024 was RMB 1,908,056 thousand, an improvement from a net loss of RMB 2,446,580 thousand in Q1 2023[17] - The company reported a total comprehensive loss of RMB -1,822,111 thousand for Q1 2024, compared to RMB -2,537,142 thousand in Q1 2023[18] Cash Flow - The net cash flow from operating activities was CNY -2,395,729,000, indicating significant cash outflow despite revenue growth[4] - Cash flow from operating activities was RMB 5,673,123 thousand in Q1 2024, compared to RMB 2,573,718 thousand in Q1 2023, indicating a 121% increase[19] - The net cash flow from operating activities was -$2,395,729, an improvement from -$3,577,897 in the previous year[21] - The total cash outflow from operating activities was $8,068,852, compared to $6,151,615 in the prior year[21] - The company experienced a net decrease in cash and cash equivalents of $708,581, an improvement from a decrease of $2,299,146 in the previous year[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 40,543,614,000, a decrease of 1.4% from the end of the previous year[5] - The total assets decreased to RMB 40,543,614 thousand in Q1 2024 from RMB 41,121,675 thousand in Q1 2023[16] - Total liabilities increased to RMB 16,425,390 thousand in Q1 2024 from RMB 16,018,333 thousand in Q1 2023[16] Shareholder Information - As of the end of the reporting period, the total number of shares issued was 1,359,524,369, with 91.54% of shares issued overseas[10] - Total number of common stock shareholders at the end of the reporting period was 38,428, a slight increase from 38,420 in the previous period[12] - The top five shareholders hold a combined total of 1,000,000,000 shares, representing approximately 47.21% of total shares[12] - The company has a total of 38,420 registered shareholders, including 38,267 domestic shareholders and 109 registered in the Cayman Islands[12] Research and Development - Research and development expenses totaled CNY 3,328,145,000, accounting for 62.10% of revenue, a decrease of 29.80 percentage points year-on-year[5] - Research and development expenses for Q1 2024 were RMB 3,328,145 thousand, up from RMB 2,818,146 thousand in Q1 2023, marking an increase of 18%[17] Inventory and Receivables - Accounts receivable increased to ¥3,101,457, up from ¥2,538,268, representing a growth of 22.2%[15] - Inventory rose to ¥3,201,045, an increase of 8.5% from ¥2,951,159 in the previous period[15] - Total current assets decreased to ¥27,986,386, down 6.1% from ¥29,810,055[15] Market and Industry Risks - The company emphasizes the high risks and long development cycles associated with the biopharmaceutical industry, which may impact future performance[14]